The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and ...

Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how incidental back pain led to an unexpected cancer diagnosis, the initial ...

Patients with (RRMM) and extramedullary disease (EMD) represent a particularly high-risk population with historically poor outcomes. In a new phase 2 analysis presented at the European Hematology ...

Panelists discuss the growing promise of GPRC5D-targeted therapy in relapsed/refractory multiple myeloma, highlighting MonumenTAL-1 trial data showing encouraging responses in heavily pretreated ...

"If patients have one feature, that is bad, and if they have two or more, that is really bad," he said. "Regardless of ...

Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced. Plasma cells are a type of white blood cell that ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis of individuals diagnosed with multiple myeloma showed that those who ...

A multi-institutional study led by the Icahn School of Medicine at Mount Sinai reports one-third of patients with relapsed or refractory multiple myeloma remained in remission for at least five ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death.

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical ...

In patients with a precursor condition for multiple myeloma, the multiple myeloma-like score helps to predict who is at a higher risk of progressing to active cancer.

Bispecific antibodies enhance immune response by targeting myeloma and immune cells, showing high efficacy in multiple myeloma treatment. Tecvvayli, Talvey, and Elrexfio demonstrate significant ...